SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Takano-Yamamoto T, Rodan GA 1990 Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats. Proc Natl Acad Sci USA 87: 21722176.
  • 2
    Lindsay R 1993 Prevention and treatment of osteoporosis. Lancet 341: 801805.
  • 3
    Spelsberg TC, Subramaniam M, Riggs BL, Khosla S 1999 The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13: 819828.
  • 4
    Pacifici R 1996 Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11: 10431051.
  • 5
    Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305311.
  • 6
    Lindberg MK, Moverare S, Skrtic S, Alatalo S, Halleen J, Mohan S, Gustafsson J-Å, Ohlsson C 2002 Two different pathways for the maintenance of trabecular bone in adult male mice. J Bone Miner Res 17: 555562.
  • 7
    Lindberg MK, Weihua Z, Andersson N, Movérare S, Gao H, Vidal NO, Erlandsson M, Windahl S, Andersson G, Lubahn DB, Carlsten H, Dahlman-Wright K, Gustafsson J-Å, Ohlsson C 2002 Estrogen receptor specificity for effects of estrogen in ovariectomized mice. J Endocrinol 174: 167178.
  • 8
    Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson J-Å, Ohlsson C 2001 Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol 171: 229236.
  • 9
    Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson J-Å, Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95: 1567715682.
  • 10
    Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90: 1116211166.
  • 11
    Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn DB, Mohan S, Gustafsson J-Å, Ohlsson C 2000 Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA 97: 54745479.
  • 12
    Windahl SH, Vidal O, Andersson G, Gustafsson J-Å, Ohlsson C 1999 Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(−/−) mice. J Clin Invest 104: 895901.
  • 13
    Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal Biochem 162: 156159.
  • 14
    Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, Gram J, Beck-Nielsen H 2000 Cytokines and bone loss in a 5-year longitudinal study—Hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: The Danish Osteoporosis Prevention Study. J Bone Miner Res 15: 15451554.
  • 15
    Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P 1999 Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest 103: 14091418.
  • 16
    Kassem M, Okazaki R, De Leon D, Harris SA, Robinson JA, Spelsberg TC, Conover CA, Riggs BL 1996 Potential mechanism of estrogen-mediated decrease in bone formation: Estrogen increases production of inhibitory insulin-like growth factor-binding protein-4. Proc Assoc Am Physicians 108: 155164.
  • 17
    Bord S, Beavan S, Ireland D, Horner A, Compston JE 2001 Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: Role of locally produced growth factors. Bone 29: 216222.
  • 18
    Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC 1991 Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 129: 33133320.
  • 19
    Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink DJ 1992 Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: Implications for estrogen deficiency-associated bone loss. Proc Natl Acad Sci USA 89: 1219012193.
  • 20
    Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M, Fujisawa R, Morito K, Masamune Y, Waki Y, Kasugai S, Miyamoto K 2001 Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142: 12281233.
  • 21
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 22
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315323.
  • 23
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 24
    Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R 2000 Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106: 12291237.
  • 25
    Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R 2001 Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 98: 1396013965.
  • 26
    Kimble RB, Vannice JL, Bloedow DC, Thompson RC, Hopfer W, Kung VT, Brownfield C, Pacifici R 1994 Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 93: 19591967.
  • 27
    Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC 1992 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89: 883891.
  • 28
    Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC 1992 Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257: 8891.
  • 29
    Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13: 11891196.
  • 30
    Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R 1994 Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94: 23972406.
  • 31
    Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL 1988 Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 8486.
  • 32
    Kusec V, Virdi AS, Prince R, Triffitt JT 1998 Localization of estrogen receptor-alpha in human and rabbit skeletal tissues. J Clin Endocrinol Metab 83: 24212428.
  • 33
    Braidman IP, Hainey L, Batra G, Selby PL, Saunders PT, Hoyland JA 2001 Localization of estrogen receptor beta protein expression in adult human bone. J Bone Miner Res 16: 214220.
  • 34
    Vidal O, Kindblom LG, Ohlsson C 1999 Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res 14: 923929.
  • 35
    Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC 1991 Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88: 66136617.
  • 36
    Manolagas SC 1995 Role of cytokines in bone resorption. Bone 17(Suppl 1):63S67S.
  • 37
    Kimble RB, Kitazawa R, Vannice JL, Pacifici R 1994 Persistent bone-sparing effect of interleukin-1 receptor antagonist: A hypothesis on the role of IL-1 in ovariectomy-induced bone loss. Calcif Tissue Int 55: 260265.
  • 38
    Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 2: 11326.
  • 39
    Chenu C, Pfeilschifter J, Mundy GR, Roodman GD 1988 Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci USA 85: 56835687.
  • 40
    Bonewald LF, Dallas SL 1994 Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem 55: 350357.
  • 41
    Centrella M, Horowitz MC, Wozney JM, McCarthy TL 1994 Transforming growth factor-beta gene family members and bone. Endocr Rev 15: 2739.
  • 42
    Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ 1995 Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270: 2042420431.
  • 43
    Schiltz PM, Mohan S, Baylink DJ 1993 Insulin-like growth factor binding protein-4 inhibits both basal and IGF-mediated chick pelvic cartilage growth in vitro. J Bone Miner Res 8: 391396.
  • 44
    Mohan S, Bautista CM, Wergedal J, Baylink DJ 1989 Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: A potential local regulator of IGF action. Proc Natl Acad Sci USA 86: 83388342.
  • 45
    Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16: 334.
  • 46
    Miyakoshi N, Richman C, Qin X, Baylink DJ, Mohan S 1999 Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 140: 57195728.
  • 47
    Auernhammer CJ, Melmed S 2000 Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21: 313345.
  • 48
    Allan EH, Hilton DJ, Brown MA, Evely RS, Yumita S, Metcalf D, Gough NM, Ng KW, Nicola NA, Martin TJ 1990 Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol 145: 110119.
  • 49
    Gouin F, Couillaud S, Cottrel M, Godard A, Passuti N, Heymann D 1999 Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. Cytokine 11: 282289.
  • 50
    Abe E, Tanaka H, Ishimi Y, Miyaura C, Hayashi T, Nagasawa H, Tomida M, Yamaguchi Y, Hozumi M, Suda T 1986 Differentiation-inducing factor purified from conditioned medium of mitogen-treated spleen cell cultures stimulates bone resorption. Proc Natl Acad Sci USA 83: 59585962.
  • 51
    Reid LR, Lowe C, Cornish J, Skinner SJ, Hilton DJ, Willson TA, Gearing DP, Martin TJ 1990 Leukemia inhibitory factor: A novel bone-active cytokine. Endocrinology 126: 14161420.
  • 52
    Cornish J, Callon K, King A, Edgar S, Reid IR 1993 The effect of leukemia inhibitory factor on bone in vivo. Endocrinology 132: 13591366.
  • 53
    Metcalf D, Gearing DP 1989 Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc Natl Acad Sci USA 86: 59485952.
  • 54
    Sabokbar A, Fujikawa Y, Brett J, Murray DW, Athanasou NA 1996 Increased osteoclastic differentiation by PMMA particle-associated macrophages. Inhibitory effect by interleukin 4 and leukemia inhibitory factor. Acta Orthop Scand 67: 593598.
  • 55
    Van Beek E, Van der Wee-Pals L, van de Ruit M, Nijweide P, Papapoulos S, Lowik C 1993 Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture. J Bone Miner Res 8: 191198.
  • 56
    Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar SA, Gliniak BC, McKenna HJ, Papayannopoulou T, Thoma B, Cheng L, Donovan PJ, Peschon JJ, Bartlett PF, Willis CR, Wright BD, Carpenter MK, Davison BL, Gearing DP 1995 Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121: 12831299.
  • 57
    Allen JE, Maizels RM 1997 Th1-Th2: Reliable paradigm or dangerous dogma? Immunol Today 18: 387392.
  • 58
    Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE 1999 The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701738.
  • 59
    Frost A, Jonsson KB, Brandstrom H, Ljunghall S, Nilsson O, Ljunggren O 2001 Interleukin (IL)-13 and IL-4 inhibit proliferation and stimulate IL-6 formation in human osteoblasts: Evidence for involvement of receptor subunits IL-13R, IL-13Ralpha, and IL-4Ralpha. Bone 28: 268274.
  • 60
    Ura K, Morimoto I, Watanabe K, Saito K, Yanagihara N, Eto S 2000 Interleukin (IL)-4 and IL-13 inhibit the differentiation of murine osteoblastic MC3T3-E1 cells. Endocr J 47: 293302.
  • 61
    Wei S, Wang MW, Teitelbaum SL, Ross FP 2001 Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-{kappa}B and MAP kinase signaling. J Biol Chem 21: 21.
  • 62
    Abu-Amer Y 2001 IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 107: 13751385.
  • 63
    Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, Seo H, Ohta H, Nozawa S, Kudo I, Suda T 1996 IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156: 758764.
  • 64
    Nakano Y, Watanabe K, Morimoto I, Okada Y, Ura K, Sato K, Kasono K, Nakamura T, Eto S 1994 Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res 9: 15331539.
  • 65
    Okada Y, Morimoto I, Ura K, Nakano Y, Tanaka Y, Nishida S, Nakamura T, Eto S 1998 Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice. Bone 22: 361365.
  • 66
    Fernandez-Botran R, Chilton PM, Ma Y, Windsor JL, Street NE 1996 Control of the production of soluble interleukin-4 receptors: Implications in immunoregulation. J Leukoc Biol 59: 499504.
  • 67
    Ma Y, Hurst HE, Fernandez-Botran R 1996 Soluble cytokine receptors as carrier proteins: Effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4. J Pharmacol Exp Ther 279: 340350.
  • 68
    Takahashi N, Udagawa N, Akatsu T, Tanaka H, Shionome M, Suda T 1991 Role of colony-stimulating factors in osteoclast development. J Bone Miner Res 6: 977985.
  • 69
    Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque JP 1998 Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 92: 34653473.
  • 70
    Soshi S, Takahashi HE, Tanizawa T, Endo N, Fujimoto R, Murota K 1996 Effect of recombinant human granulocyte colony-stimulating factor (rh G-CSF) on rat bone: Inhibition of bone formation at the endosteal surface of vertebra and tibia. Calcif Tissue Int 58: 337340.
  • 71
    Takahashi T, Wada T, Mori M, Kokai Y, Ishii S 1996 Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice. Lab Invest 74: 827834.